UK markets close in 5 hours 9 minutes
  • FTSE 100

    7,460.58
    -93.73 (-1.24%)
     
  • FTSE 250

    21,674.57
    -180.00 (-0.82%)
     
  • AIM

    1,080.23
    -6.41 (-0.59%)
     
  • GBP/EUR

    1.2025
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.3387
    +0.0006 (+0.04%)
     
  • BTC-GBP

    27,278.96
    -110.46 (-0.40%)
     
  • CMC Crypto 200

    828.39
    +8.88 (+1.08%)
     
  • S&P 500

    4,326.51
    -23.42 (-0.54%)
     
  • DOW

    34,160.78
    -7.31 (-0.02%)
     
  • CRUDE OIL

    86.84
    +0.23 (+0.27%)
     
  • GOLD FUTURES

    1,782.70
    -12.30 (-0.69%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     
  • HANG SENG

    23,550.08
    -256.92 (-1.08%)
     
  • DAX

    15,231.66
    -292.61 (-1.88%)
     
  • CAC 40

    6,917.02
    -106.78 (-1.52%)
     

Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • ZEAL
  • ZLDPF

Company announcement – No. 1 / 2022

Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference

Copenhagen, DK and Boston, MA, U.S. January 3, 2022Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate in the H.C. Wainwright BIOCONNECT 2022 Conference:

H.C. Wainwright BIOCONNECT 2022 Conference
Date: Monday, January 10, 2022
Presentation: 7:00 a.m. EST / 12:00 p.m. GMT / 1:00 p.m. CET

A pre-recorded webcast of the presentation will be available at the time of the presentation on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor Relations

Maeve Conneighton

Argot Partners

investors@zealandpharma.com

Zealand Pharma Media Relations

David Rosen

Argot Partners

media@zealandpharma.com










Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting